Local treatment of chloasma in pregnant women

Cover Page

Cite item


Goal. To assess the efficacy and safety of Azelic (15% gel of azelaic acid for topical administration) for the treatment of chloasma in pregnant women. Materials and methods. The study involved 28 pregnant women aged 18-36 (mean age: 24.7) with a normal course of pregnancy. The patients consulted a doctor in the spring, summer or fall complaining of focal skin hyperpigmentation on the face, chin and chest area. Ten patients (35.7%) developed hyperpigmentation prior to their pregnancy and 18 women (64.3%) - during the pregnancy. As of the consultation date, the pregnancy terms in all of the patients were 18-20 weeks. Chloasma was diagnosed by using dermatoscopy and skin examination with the Wood’s lamp. The patients were informed about the content and procedure of the study and gave their consent to take part in the study. Thin layers of Azelic (15% gel of azelaic acid for topical administration) were applied to the hyperpigmented skin of the patients and gently rubbed twice a day (in the morning and evening) as topical treatment for four months. The treatment results were assessed taking into consideration the patient’s subjective assessment, study group structure depending on the clinical efficacy, percentage of adverse events, and survey results based on the Dermatology Life Quality Index questionnaire. To reveal any potential general toxicological effects of the treatment, hepatic samples, total blood count and coagulogram results were analyzed as a part of obstetrical and gynecologic care for pregnant women. Key findings. Positive dynamics of the following characteristics was revealed: subjective assessment of treatment results by the patients, clinical efficacy of treatment and life quality index. Therapeutic results were observed as early as after one month but not later than three months after the treatment began. The therapeutic efficacy was recorded in 92.9-96.4% of all cases after four months of treatment: pigment spots disappeared or became paler, and their dimensions and their contrast as compared to the healthy skin reduced, the skin texture and life quality improved (the Dermatology Life Quality Index reduced from 15.5 ± 1.8 to 6.7 ± 0.5 points against the background of the treatment efficacy: from severe to moderate impact of the disease on the patient’s life, respectively). Five women (17.9%) developed erythema and burning sensations in the drug application site within the first two weeks immediately after the gel application (one of the patients had the same symptoms for six weeks of the treatment); the symptoms were weak and transient and did not require any additional treatment. Hepatic samples, total blood count and coagulogram results were within physiological standards during the treatment. Conclusion. Topical application of Azelic (15% gel of azelaic acid for topical administration) twice a day for four months is an efficient and safe method to treat chloasma in pregnant women.

About the authors

N. V. Shperling

Research and Testing Institute (Military Medicine), Military Medical Academy named S.M. Kirov Russian Defense Ministry; International Medical Center «Time»

Author for correspondence.
Email: noemail@neicon.ru
Russian Federation

A. I. Vengerovsky

Siberian State Medical University, Ministry of Healthcare of the Russian Federation

Email: noemail@neicon.ru
Russian Federation

I. A. Shperling

Research and Testing Institute (Military Medicine), Military Medical Academy named S.M. Kirov Russian Defense Ministry

Email: shperling2@yandex.ru
Russian Federation

E. V. Romanova

Siberian State Medical University, Ministry of Healthcare of the Russian Federation

Email: noemail@neicon.ru
Russian Federation


  1. Болотная Л.А., Сербина И.М., Бей Л.И. Нарушения пигментации кожи и их коррекция в дерматокосметологической практике. Український журнал дерматології, венерології, косметологі 2003; (3): 34-38
  2. Гейниц А.В., Москвин С.В. Лазерная терапия в косметологии и дерматологии. М; Тверь: Триада, 2010
  3. Должникова Э.М. Патогенетические аспекты старения кожи. Expo Beauty Esthetic Forum. М., 2003
  4. Европейское руководство по лечению дерматологических болезней / Под ред. А.Д. Кацамбаса, Т.М. Лотти; пер. с англ. 3-е изд. М.: МЕД-пресс-информ, 2014
  5. Исмайлов Р.Г. Регуляция меланогенеза при дисхромии кожи. Вестник Российской Академии медицинских наук 2014; (1): 85-92
  6. Касихина Е.И. Гиперпигментация: современные возможности терапии и профилактики. Лечащий врач 2011; (6): 73-76
  7. Кошевенко Ю.Н. Проблемы психосоматики в дерматокосметологии. Косметика и медицина 2002; (2): 18-25
  8. Нетруненко И.Ю., Игнатьев Д.В. Пигментация: проблемы и пути их решения. Consillium Medicum 2007; (2): 12-16
  9. Николаев А.Я. Биологическая химия. 3-е изд., переаб. и доп. М.: Медицинское информационное агентство, 2004
  10. Потекаев Н.Н., Круглова Л.С. Гиперпигментация: причины возникновения и методы коррекции. Клиническая дерматология и венерология 2012; (6): 65-70
  11. Руководство по дерматокосметологии / Под ред. Е.Р. Аравийской, Е.В. Соколовского. СПб: Фолиант, 2008
  12. Федеральные клинические рекомендации по ведению больных акне. Российское общество дерматовенерологов, М, 2013
  13. Хавина Е. Комплексная программа коррекции гиперпигментации в практике косметолога. KOSMETIK international 2010; (5): 10-15
  14. Basketter D.A., Reynolds F.S., York M. Predictive Testing in contact Dermatitis, irritant. Dermatitis Clin Dermatol 1997; 15 (4): 637-644.
  15. Berlin A.L., Paller A.S., Chan L.S. Incontinentia pigmenti: A review and update on the molecular basis of pathophysiology. J Am Acad Dermatol 2002; 47 (2 Pt 1): 169-187.
  16. Dessinioti C., Antoniou C., Katsambas A., Stratigos A.J. Melanocortin 1 receptor variants: functional role and pigmentary associations. Photochem Photobiol 2011; 87 (5): 978-987.
  17. Fluhr J.W., Degitz K. Antibiotics, azelaic acid and benzoyl peroxide in topical acne therapy. J Dtsch Dermatol Ges., 2010; 3 (8) Suppl 1: 24-30.
  18. Goodman G.J., Baron J.A. The management of postacne scarring. Dermatol Surg 2007; (33): 1175-1188.
  19. Imokawa G. Autocrine and paracrine regulation of melanocytes in human skin and in pigmentary disorders. Pigment Cell Res 2004; 17: 96-110.
  20. Jang Y.H., Lee J.Y., Kang H.Y. et al. Oestrogen and progesterone receptor expression in melasma: an immunohistochemical analysis. J Eur Acad Dermatol Venereol 2010; Nov; 24 (11): 1312-1316.
  21. Katsambas A., Antoniou C. Melasma. Classification and treatment. J Eur Acad Dermatol Ven-ero1 1995; 4: 217-223.
  22. Katsambas A.D., Stratigos A.J. Depigmenting and Bleaching Agents: Coping with Hyperpigmentation. Clinics in Dermatology 2001; 19: 483-488.
  23. Nicolaidou E., Katsambas A.D. Pigmentation disorders: hyperpigmentation and hypopigmentation. Clin Dermatol 2014; 32 (1): 66-72.
  24. Sanchez W.Y., Obispo C., Ryan E., Grice J.E., Roberts M.S. Changes in the redox state and endogenous fluorescence of in vivo human skin due to intrinsic andphoto-aging, measured by multiphoton tomography with fluorescence lifetime imaging. J. Biomed Opt 2013; 18 (6): 217.
  25. Walker A.P., Basketter D.A., Baverel M. et al. Test Guidelines for the assessment of the skin tolerance of potentially irritant cosmetic ingredients in man. European Cosmetic, Toiletry and Perfumery Association. Food Chem Technol 1997; 37: 1099-1160.
  26. Yokota T., Nishio H., Kubota Y., Mizoguchi M. The inhibitory effect of glabridin from licorice extracts on melanogenesis and inflammation. Pigment Cell Res 1998; 11: 355-361.

Copyright (c) 2014 Shperling N.V., Vengerovsky A.I., Shperling I.A., Romanova E.V.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ПИ № ФС 77 - 60448 от 30.12.2014.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies